Tags

Type your tag names separated by a space and hit enter

Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies.

Abstract

This is a dose-response (DR) meta-analysis to evaluate the association of coffee consumption on endometrial cancer (EC) risk. A total 1,534,039 participants from 13 published articles were added in this meta-analysis. The RR of total coffee consumption and EC were 0.80 (95% CI: 0.74-0.86). A stronger association between coffee intake and EC incidence was found in patients who were never treated with hormones, 0.60 (95% CI: 0.50-0.72), and subjects with a BMI ≥25 kg/m(2), 0.57 (95% CI: 0.46-0.71). The overall RRs for caffeinated and decaffeinated coffee were 0.66 (95% CI: 0.52-0.84) and 0.77 (95% CI: 0.63-0.94), respectively. A linear DR relationship was seen in coffee, caffeinated coffee, decaffeinated coffee and caffeine intake. The EC risk decreased by 5% for every 1 cup per day of coffee intake, 7% for every 1 cup per day of caffeinated coffee intake, 4% for every 1 cup per day of decaffeinated intake of coffee, and 4% for every 100 mg of caffeine intake per day. In conclusion, coffee and intake of caffeine might significantly reduce the incidence of EC, and these effects may be modified by BMI and history of hormone therapy.

Links

  • PMC Free PDF
  • PMC Free Full Text
  • FREE Publisher Full Text
  • Authors+Show Affiliations

    ,

    Department of Science and Education, First People's Hospital of Changde City, Changde 415003, Hunan, People's Republic of China.

    ,

    Changsha Center for Disease Control and Prevention, Changsha 410001, Hunan, People's Republic of China.

    ,

    Department of Oncology, First People's Hospital of Changde City, Changde 415003, Hunan, People's Republic of China.

    ,

    Department of Neurology, Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, People's Republic of China.

    Department of Oncology, Affiliated Hospital of Zunyi Medical University, Address: NO.149, Dalian Road, Zunyi City, Guizhou Province, China, 653000.

    Source

    Scientific reports 5: 2015 Aug 25 pg 13410

    MeSH

    Adult
    Age Distribution
    Aged
    Caffeine
    Causality
    Coffee
    Cohort Studies
    Drinking Behavior
    Endometrial Neoplasms
    Female
    Hormone Replacement Therapy
    Humans
    Incidence
    Middle Aged
    Prospective Studies
    Risk Assessment

    Pub Type(s)

    Journal Article
    Meta-Analysis
    Review

    Language

    eng

    PubMed ID

    26302813

    Citation

    Zhou, Quan, et al. "Coffee Consumption and Risk of Endometrial Cancer: a Dose-response Meta-analysis of Prospective Cohort Studies." Scientific Reports, vol. 5, 2015, p. 13410.
    Zhou Q, Luo ML, Li H, et al. Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. Sci Rep. 2015;5:13410.
    Zhou, Q., Luo, M. L., Li, H., Li, M., & Zhou, J. G. (2015). Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. Scientific Reports, 5, p. 13410. doi:10.1038/srep13410.
    Zhou Q, et al. Coffee Consumption and Risk of Endometrial Cancer: a Dose-response Meta-analysis of Prospective Cohort Studies. Sci Rep. 2015 Aug 25;5:13410. PubMed PMID: 26302813.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Coffee consumption and risk of endometrial cancer: a dose-response meta-analysis of prospective cohort studies. AU - Zhou,Quan, AU - Luo,Mei-Ling, AU - Li,Hui, AU - Li,Min, AU - Zhou,Jian-Guo, Y1 - 2015/08/25/ PY - 2015/03/11/received PY - 2015/07/27/accepted PY - 2015/8/26/entrez PY - 2015/8/26/pubmed PY - 2016/7/28/medline SP - 13410 EP - 13410 JF - Scientific reports JO - Sci Rep VL - 5 N2 - This is a dose-response (DR) meta-analysis to evaluate the association of coffee consumption on endometrial cancer (EC) risk. A total 1,534,039 participants from 13 published articles were added in this meta-analysis. The RR of total coffee consumption and EC were 0.80 (95% CI: 0.74-0.86). A stronger association between coffee intake and EC incidence was found in patients who were never treated with hormones, 0.60 (95% CI: 0.50-0.72), and subjects with a BMI ≥25 kg/m(2), 0.57 (95% CI: 0.46-0.71). The overall RRs for caffeinated and decaffeinated coffee were 0.66 (95% CI: 0.52-0.84) and 0.77 (95% CI: 0.63-0.94), respectively. A linear DR relationship was seen in coffee, caffeinated coffee, decaffeinated coffee and caffeine intake. The EC risk decreased by 5% for every 1 cup per day of coffee intake, 7% for every 1 cup per day of caffeinated coffee intake, 4% for every 1 cup per day of decaffeinated intake of coffee, and 4% for every 100 mg of caffeine intake per day. In conclusion, coffee and intake of caffeine might significantly reduce the incidence of EC, and these effects may be modified by BMI and history of hormone therapy. SN - 2045-2322 UR - https://www.unboundmedicine.com/medline/citation/26302813/full_citation L2 - http://dx.doi.org/10.1038/srep13410 DB - PRIME DP - Unbound Medicine ER -